Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer—Response

1 Apr 2014

Abstract excerpt

In a Letter to the Editor about our recent publication (1), Haifeng Qiu suggests that further clarification is needed about the relationship between sensitivity to BMN 673 and dysregulated PI3K/mTOR signaling, given the potential association between PTEN loss and PARP inhibitor sensitivity in other cancer types.Although we agree that PTEN inactivation is common in human malignancies and may be associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24687924
DOI: 10.1158/1078-0432.ccr-13-3391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer—ResponsePMID 24687924Read ↗

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung CancerSemantic proximity Read ↗

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerSemantic proximity Read ↗

PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implicationsSemantic proximity Read ↗

Induced Degradation of Lineage-specific Oncoproteins Drives the Selective PARP1 Inhibitor Toxicity in Small Cell Lung CancerSemantic proximity Read ↗

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.Semantic proximity Read ↗

PTEN Mutant Non-Small Cell Lung Cancer Require ATM to Suppress Pro-Apoptotic Signalling and Evade RadiotherapySemantic proximity Read ↗

PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers.Semantic proximity Read ↗

Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.